UBE3C and head and neck cancer: Designing a prospective study with a large cohort of patients is warranted to provide detailed information on fusion gene prevalence, correlation with clinicopathological features and patient survival, and establish UBE3C-LRP5 fusion as a therapeutic target in head and neck cancer.